SCHEMBL24870735

SCHEMBL24870735

NCc1cc(Nc2nccn3c(-c4ccc(OC(F)F)cc4)cnc23)ccc1C(=O)N1CCC(CN)CC1

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ PTK6 Q13882 7/20 0.47
▸ MAPKAPK5 Q8IW41 3/20 0.41
▸ TTK P33981 10/20 0.41
▸ LCK P06239 3/20 0.38
▸ AURKB Q96GD4 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22123920 0.95 PTK6 (0.46) PTK6MAPKAPK5TTKLCKAURKB
SCHEMBL25444717 0.93 PTK6 (0.45) PTK6MAPKAPK5TTKLCKAURKB
SCHEMBL22125340 0.92 PTK6 (0.47) PTK6MAPKAPK5TTKLCKAURKB
SCHEMBL30201986 0.92 PTK6 (0.47) PTK6MAPKAPK5TTKLCKAURKB
SCHEMBL22124582 0.92 PTK6 (0.47) PTK6MAPKAPK5TTKLCKAURKB
SCHEMBL22125271 0.92 PTK6 (0.47) PTK6MAPKAPK5TTKLCKAURKB
Hydrochloric Acid SCHEMBL30171999 0.91 PTK6 (0.46) PTK6MAPKAPK5TTKLCKAURKB
Hydrochloric Acid SCHEMBL30172098 0.91 PTK6 (0.46) PTK6MAPKAPK5TTKLCKAURKB
SCHEMBL22125501 0.90 PTK6 (0.45) PTK6MAPKAPK5TTKLCKAURKB
SCHEMBL22160990 0.90 PTK6 (0.45) PTK6MAPKAPK5TTKLCKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230022724-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-26 — — US disclosed
US-20230013602-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-19 — — US disclosed
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-19 — — US disclosed
EP-3898629-B1 IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS HOFFMANN LA ROCHE (CH) 2023-01-18 — — EP disclosed
US-20230012368-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022724-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES MRPL21, O60361, MYD88 PTK6 2201/4885MAPKAPK5 728/4885TTK 4546/4885
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES MRPL21, O60361, MYD88 PTK6 2141/4885MAPKAPK5 695/4885TTK 4573/4885
US-20230013602-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES IL4, RPS4Y1, RPS4X PTK6 1818/4885MAPKAPK5 516/4885TTK 4519/4885
US-20230012368-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES MRPL21, MYD88, IL1R1 PTK6 2211/4885MAPKAPK5 647/4885TTK 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback